Representative image
HYDERABAD: Vaccine maker Bharat Biotech on Wednesday said it has entered into a product transfer agreement with pharma giant GSK and global non-profit PATH for the world’s only malaria vaccine RTS, S/AS01E1 that was developed by GSK.
The pact includes the transfer of manufacturing of the RTS, S antigen part of the vaccine as well as the grant of a licence on all rights pertaining to RTS, S/AS01 malaria vaccine to Bharat Biotech.
With this, by 2029, Bharat Biotech will be the sole supplier of the vaccine. However, GSK will retain production of the vaccine’s adjuvant AS01E, which it will supply to Bharat Biotech.
Hyderbad |
Updated on
× GSK, PATH, and Bharat Biotech (BBIL) have entered into a product transfer agreement for malaria vaccine.
The agreement includes the transfer of manufacturing of the RTS,antigen part of the vaccine and the grant of a licence on all rights pertaining to the RTS,S/AS01 malaria vaccine to BBIL. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to BBIL.
“The agreement recognises the track record and expertise of BBIL in developing and supplying vaccines against infectious diseases, including as an established supplier of global health vaccines to Gavi, the Vaccine Alliance, and to UNICEF,” Hyderabad-based Bharat Biotech said in a release on Wednesday.
GSK, PATH, Bharat Biotech join hands for novel malaria vaccine
GSK, PATH, Bharat Biotech join hands for novel malaria vaccine
27 January 2021 | News Bharat Biotech to produce antigen for world’s first vaccine against Plasmodium falciparum malaria
GSK, PATH, and Bharat Biotech (BBIL) have announced the signing of a product transfer agreement for the malaria vaccine, RTS,S/AS01E 1. The agreement includes the transfer of manufacturing of the RTS,S antigen part of the vaccine and the grant of a license on all rights pertaining to the RTS,S/AS01 malaria vaccine to BBIL. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to BBIL.